DCR PHXC

Drug Profile

DCR PHXC

Alternative Names: DCR-PHXC

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dicerna Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action Oxalate modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Primary hyperoxaluria

Most Recent Events

  • 08 Mar 2018 Dicerna plans to submit CTAs for the PHYOX study in other European countries in 2019
  • 08 Mar 2018 Dicerna plans a multi-dose phase II/III trial for Primary hyperoxaluria in first quarter of 2019
  • 07 Dec 2017 Phase-I clinical trials in Primary hyperoxaluria in United Kingdom (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top